Generic Name: elvitegravir
Other Market Name: N/A
Drug Class: Integrase Inhibitors
Pharmaceutical Company: Gilead Sciences
Approval Status: Approved
Generic Version Available: No
Experimental Code: GS-9137
Part of a recommended DHHS regimen for treatment-naïve patients.
Visit http://aidsinfo.nih.gov/contentfiles/lvguidelines/aa_recommendations.pdf for the full DHHS guidelines.
Vitekta is an HIV medication. It is in a category of HIV medicines called integrase inhibitors. Vitekta was approved by the U.S. Food and Drug Administration for use by people living with HIV in September 2014.
Vitekta is available as a single drug or in the fixed-dosed combination drug Stribild.
Vitekta must be used in combination with a Norvir (ritonavir)-boosted protease inhibitor and another HIV drug.
Adult Dose: One 85 mg tablet once a day when taken with twice-daily Kaletra (lopinavir) or once-daily Reyataz (atazanavir)/Norvir (ritonavir)
One 150 mg tablet once a day when taken with twice-daily Lexiva (fosamprenavir)/Norvir (ritonavir), Prezista (darunavir)/Norvir (ritonavir) or Aptivus (tipranavir)/Norvir (ritonavir)
Pediatric Dose: N/A
Dosing Info: Take with food.
The most common side effect of Vitekta is diarrhea.
The risk and severity of other side effects will depend on the other HIV drug components of the regimen used.
For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Vitekta or may require dose adjustments, consult the Vitekta package insert: http://www.gilead.com/~/media/Files/pdfs/medicines/hiv/vitekta/vitekta_pi.pdf
Before taking this medication, tell your doctor if you have kidney disease or liver disease (including hepatitis B. In addition, tell your doctor if you are pregnant or planning to become pregnant, if you are breast feeding, and all your medical conditions, including all prescription and over-the-counter medications and supplements you are taking.
Co-Pay Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Patient Assistance Program Info: https://www.poz.com/basics/hiv-basics/drug-assistance-programs
Last Revised: January 13, 2016